Novavax, Inc. (NASDAQ:NVAX) shot up 11.7% during trading on Monday . The stock traded as high as $1.70 and last traded at $1.82. 599,255 shares changed hands during trading, a decline of 87% from the average session volume of 4,530,302 shares. The stock had previously closed at $1.63.

Several brokerages have commented on NVAX. Zacks Investment Research upgraded shares of Novavax from a “hold” rating to a “buy” rating and set a $1.50 target price on the stock in a research report on Tuesday, August 14th. BidaskClub lowered shares of Novavax from a “hold” rating to a “sell” rating in a research report on Wednesday, June 6th. JPMorgan Chase & Co. upgraded shares of Novavax from an “underweight” rating to an “overweight” rating and boosted their price objective for the stock from $2.00 to $2.25 in a research report on Friday. Finally, ValuEngine upgraded shares of Novavax from a “sell” rating to a “hold” rating in a research report on Saturday, June 2nd. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and five have given a buy rating to the company. Novavax currently has an average rating of “Hold” and a consensus target price of $3.37.

The company has a debt-to-equity ratio of -3.63, a quick ratio of 4.52 and a current ratio of 4.52. The stock has a market capitalization of $612.15 million, a P/E ratio of -2.60 and a beta of 2.61.

Novavax (NASDAQ:NVAX) last released its quarterly earnings data on Wednesday, August 8th. The biopharmaceutical company reported ($0.12) EPS for the quarter, hitting the consensus estimate of ($0.12). The business had revenue of $10.80 million during the quarter, compared to analysts’ expectations of $10.02 million. During the same quarter in the prior year, the firm earned ($0.16) earnings per share. Novavax’s quarterly revenue was up 61.2% on a year-over-year basis. analysts expect that Novavax, Inc. will post -0.54 EPS for the current year.

Institutional investors have recently added to or reduced their stakes in the stock. Millennium Management LLC lifted its holdings in Novavax by 338.9% in the 1st quarter. Millennium Management LLC now owns 5,319,314 shares of the biopharmaceutical company’s stock valued at $11,171,000 after purchasing an additional 4,107,352 shares in the last quarter. UBS Group AG lifted its holdings in Novavax by 513.2% in the 1st quarter. UBS Group AG now owns 1,611,084 shares of the biopharmaceutical company’s stock valued at $3,383,000 after purchasing an additional 1,348,341 shares in the last quarter. Eagle Asset Management Inc. purchased a new position in Novavax in the 2nd quarter valued at about $1,675,000. Northern Trust Corp lifted its holdings in Novavax by 22.0% in the 2nd quarter. Northern Trust Corp now owns 4,429,972 shares of the biopharmaceutical company’s stock valued at $5,935,000 after purchasing an additional 797,965 shares in the last quarter. Finally, Rock Springs Capital Management LP lifted its holdings in Novavax by 37.5% in the 1st quarter. Rock Springs Capital Management LP now owns 2,750,000 shares of the biopharmaceutical company’s stock valued at $5,775,000 after purchasing an additional 750,000 shares in the last quarter. Institutional investors and hedge funds own 43.98% of the company’s stock.

Novavax Company Profile (NASDAQ:NVAX)

Novavax, Inc, together with its subsidiary, Novavax AB, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of recombinant nanoparticle vaccines and adjuvants. Its lead adjuvant is Matrix-M that is used to enable a vaccine to enhance the amplitude of the immune response and qualitatively change it, enhance its specificity to provide protection against related microorganisms, as well as allows immunization with much lower doses of antigen.

Read More: Do stock splits help investors?

Receive News & Ratings for Novavax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novavax and related companies with MarketBeat.com's FREE daily email newsletter.